NanoCelle Acipimoc (NC-API) - Drug Programme

Muscle tissue loss is a sign of aging, affecting all ages and both sexes without discrimination. What if we could slow this procress?

Beyond physical aging, disease and hospital settings are strongly associated with elevated sarcopenia prevalence

  
  Sarcopenia prevalence by population / context (U.S.)
  
      Population / Context
      Approx. Sarcopenia Prevalence
    
      General population <60 years
      ~10–15%
    
      Age 60–80 years
      ~20–30%
    
      Age 80+ years
      >40%, up to ~50%
    
      Trauma patients (all ages)
      ~36%
    
      Trauma patients 80+
      ~82%
    
      Chronic disease groups
      18% (diabetes) to 66% (esophageal cancer)
    
      Hospital/ICU settings
      10–70% (depending on setting)

PROGRESSION STATUS

Principle Agency: FDA

Proposed Pathway: 505(b)(1)

Initial Indication: Sacropenia and Mitrochonrial Health

Claim Expansion: Unsure

Next: Pre-clinical

Next Trial: n/a

EA-IND : Applications closed at this time

Physician Led IND: Applications closed at this time